Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 4,010,000 shares, a decrease of 10.3% from the December 15th total of 4,470,000 shares. Currently, 7.7% of the shares of the company are sold short. Based on an average trading volume of 541,400 shares, the days-to-cover ratio is presently 7.4 days.
A number of analysts recently issued reports on VNDA shares. ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 27th. Citigroup cut Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 price objective on the stock. in a report on Thursday, November 7th. Stifel Nicolaus reissued a “hold” rating and set a $17.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, November 7th. Finally, Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Saturday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.80.
In other news, CFO James Patrick Kelly sold 4,020 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $15.94, for a total transaction of $64,078.80. Following the completion of the transaction, the chief financial officer now owns 205,726 shares in the company, valued at approximately $3,279,272.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mihael Hristos Polymeropoulos sold 9,467 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $16.00, for a total value of $151,472.00. Following the transaction, the chief executive officer now owns 1,234,579 shares of the company’s stock, valued at approximately $19,753,264. The disclosure for this sale can be found here. Insiders have sold a total of 14,642 shares of company stock valued at $234,100 in the last quarter. 8.20% of the stock is owned by corporate insiders.
VNDA remained flat at $$15.15 during trading on Tuesday. The company had a trading volume of 935,341 shares, compared to its average volume of 557,293. The company has a 50-day simple moving average of $16.69 and a 200-day simple moving average of $14.66. The stock has a market cap of $807.79 million, a P/E ratio of 31.55 and a beta of 0.36. Vanda Pharmaceuticals has a twelve month low of $11.83 and a twelve month high of $31.30.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $1.77. The business had revenue of $59.49 million for the quarter, compared to analysts’ expectations of $58.33 million. Vanda Pharmaceuticals had a return on equity of 38.90% and a net margin of 55.49%. The firm’s quarterly revenue was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.13 EPS. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals will post 2.16 EPS for the current year.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Featured Story: Trading Stocks – What are percentage gainers?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.